Late-breaking data on atopic dermatitis treatments was presented, with some reports indicating promising results, including high response rates and rapid improvement. The data includes results from a phase 2 trial of a treatment for pediatric atopic dermatitis, as well as a dual JAK/TYK2 inhibitor. The specifics of the treatments and their outcomes are varied, with some reports highlighting novel therapies and others discussing specific drug successes.